To the Editor It is with my great surprise that the study by Sparano et al1 was published in JAMA Oncology. In this high-risk group of participants with breast cancer with a recurrence score of 26 to 100, the treatment was not randomized. The statistical methods for projection of clinical outcomes were also estimated. The authors used National Surgical Adjuvant Breast and Bowel Project (NSABP) B20 data, but the trial’s prospective period was from October 1988 to March 1993, which predates the Oncotype DX recurrence score assay (Genomic Health, first available in 2003).
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Lee F. Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer. JAMA Oncol. Published online February 13, 2020. doi:10.1001/jamaoncol.2019.6709
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: